We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel DNA Vaccine Prevents AD in Mouse Model

By LabMedica International staff writers
Posted on 04 Dec 2018
Print article
Image: Toxic amyloid plaques (red) and tau tangles (brown) form on the brain of a mouse modeled to have Alzheimer\'s disease. This study shows that a DNA vaccine reduces both amyloid and tau in the mouse AD model, with no adverse immune responses (Photo courtesy of the University of Texas Southwestern Medical Center).
Image: Toxic amyloid plaques (red) and tau tangles (brown) form on the brain of a mouse modeled to have Alzheimer\'s disease. This study shows that a DNA vaccine reduces both amyloid and tau in the mouse AD model, with no adverse immune responses (Photo courtesy of the University of Texas Southwestern Medical Center).
A team of Alzheimer's disease (AD) researchers has shown that a DNA vaccine directed at the toxic Abeta42 peptide protected the animals comprising a mouse (AD) model from both amyloid plaques and pathogenic tau tangles.

Amyloid deposition and hyperphosphorylation of tau protein are both pathological characteristics of AD. Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) had demonstrated previously that a vaccine based on Abeta42 peptide could reduce buildup of amyloid plaques and tau tangles, but with unacceptably severe side effects.

In the current study, the investigator used a triple-transgenic mouse model (3xTg-AD) that developed plaques and tangles in the brain similar to human AD. Four cohorts of between 15 and 24 mice each were injected in the skin with DNA coding for the Abeta42 peptide. The researchers had shown previously that full-length DNA Abeta42 trimer immunization was non-inflammatory and induced a regulatory immune response.

Results published in the November 20, 2018, online edition of the journal Alzheimer's Research and Therapy revealed that the vaccine caused a 40% reduction in beta-amyloid and up to a 50% reduction in tau compared with non-immunized 3xTg-AD control animals, with no adverse immune response.

Genes encoded by the DNA in the vaccine were expressed within the skin, and the peptides were taken up by dendritic cells traveling to the regional lymph nodes and presenting the antigen to B- and T-cells. Immunotherapy with DNA Abeta42 trimer led to reduction of Abeta40/Abeta42 peptides and amyloid plaques, and as shown here for the first time, DNA Abeta42 trimer immunization led also to significant reduction of tau from the brains of the mice.

"If the onset of the disease could be delayed by even five years, that would be enormous for the patients and their families," said senior author Dr. Doris Lambracht-Washington, assistant professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center. "The number of dementia cases could drop by half."

Related Links:
University of Texas Southwestern Medical Center

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.